Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, January 10th. The firm currently has a $105.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential downside of 15.72% from the stock’s previous close.
According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
MDGL has been the topic of a number of other research reports. HC Wainwright began coverage on Madrigal Pharmaceuticals in a research note on Wednesday, November 29th. They set a “buy” rating and a $54.00 price objective for the company. Roth Capital set a $82.00 price objective on Madrigal Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 30th. JMP Securities upped their price objective on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the stock an “outperform” rating in a research note on Friday, October 13th. Finally, Evercore ISI increased their price target on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, December 7th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $129.00.
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded up $12.92 during midday trading on Wednesday, reaching $124.59. The company had a trading volume of 356,062 shares, compared to its average volume of 115,155. Madrigal Pharmaceuticals has a one year low of $13.09 and a one year high of $127.80.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.11. analysts anticipate that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. acquired a new stake in Madrigal Pharmaceuticals in the second quarter valued at approximately $225,000. Bank of New York Mellon Corp acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $179,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $120,000. New York State Common Retirement Fund acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $109,000. Finally, Citigroup Inc. acquired a new stake in shares of Madrigal Pharmaceuticals in the second quarter worth approximately $185,000. 19.10% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/madrigal-pharmaceuticals-mdgl-upgraded-at-zacks-investment-research.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.